参考文献/References:
[1] Farrell KB,Karpeisky A,Thamm DH,et al.Bisphosphonate conjugation for bone specific drug targeting [J].Bone Rep,2018,9:47-60.DOI:10.1016/j.bonr.2018.06.007.
[2] Ganesan K,Goyal A.Bisphosphonate //Roane D.Statpearls[M].Treasure Island(FL):StatPearls Publishing LLC,2022:333-354.
[3] Otto S,Pautke C,Van den Wyngaert T,et al.Medication-related osteonecrosis of the jaw:prevention,diagnosis and management in patients with cancer and bone metastases [J].Cancer Treat Rev,2018,69:177-187.DOI:10.1016/j.ctrv.2018.06.007.
[4] 夏维波,章振林,林华,等.原发性骨质疏松症诊疗指南(2017)[J].中国骨质疏松杂志,2019,25(3):281-309.DOI:10.3969/j.issn.1674-2591.2017.05.002.
[5] Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].N Engl J Med,2007,356(18):1809-1822.DOI:10.1056/NEJMoa067312.
[6] Reid IR,Gamble GD,Mesenbrink P,et al.Characterization of and risk factors for the acute-phase response after zoledronic acid [J].J Clin Endocrinol Metab,2010,95(9):4380-4387.DOI:10.1210/jc.2010-0597.
[7] Merlotti D,Rendina D,Gennari L,et al.Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone [J].J Bone Miner Res,2011,26(3):512-518.DOI:10.1002/jbmr.237.
[8] Viapiana O,Idolazzi L,Fassio A,et al.Long-term effects of neridronate in adults with osteogenesis imperfecta:an observational three-year Italian study [J].Calcif Tissue Int,2017,100(4):341-347.DOI:10.1007/s00223-017-0236-9.
[9] Sieber P,Lardelli P,Kraenzlin CA,et al.Intravenous bisphosphonates for postmenopausal osteoporosis:safety profiles of zoledronic acid and ibandronate in clinical practice [J].Clin Drug Investig,2013,33(2):117-122.DOI:10.1007/s40261-012-0041-1.
[10] Adami S,Bhalla AK,Dorizzi R,et al.The acute-phase response after bisphosphonate administration [J].Calcif Tissue Int,1987,41(6):326-331.DOI:10.1007/BF02556671.
[11] Ganesan K,Bansal P,Goyal A,et al.Bisphosphonate.Statpearls[M].Treasure Island(FL):StatPearls Publishing LLC,2021.
[12] Takimoto R,Suzawa T,Yamada A,et al.Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of γδ T cells [J].Immunology,2021,162(3):306-313.DOI:10.1111/imm.13283.
[13] Ding Y,Zeng JC,Yin F,et al.Multicenter study on observation of acute-phase responses after infusion of zoledronic acid 5 mg in Chinese women with postmenopausal osteoporosis [J].Orthop Surg,2017,9(3):284-289.DOI:10.1111/os.12338.
[14] Weber DR,Diaz MCG,Louis S,et al.A quality improvement project to address the challenges surrounding zoledronic acid use in children [J].J Bone Miner Metab,2021,39(4):693-699.DOI:10.1007/s00774-021-01214-5.
[15] Popp AW,Senn R,Curkovic I,et al.Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate [J].Osteoporos Int,2017,28(6):1995-2002.DOI:10.1007/s00198-017-3992-5.
[16] Chen FP,Fu TS,Lin YC,et al.Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion [J].Osteoporos Int,2021,32(4):663-670.DOI:10.1007/s00198-020-05653-0.
[17] Shiraki M,Kuroda T,Takeuchi Y,et al.Acute phase reactions after intravenous infusion of zoledronic acid in Japanese patients with osteoporosis:sub-analyses of the phase iii zone study [J].Calcif Tissue Int,2021,109(6):666-674.DOI:10.1007/s00223-021-00884-7.
[18] Santini D,Vincenzi B,Caraglia M,et al.A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss [J].Ann Oncol,2007,18(1):201-202.DOI:10.1093/annonc/mdl298.
[19] Crotti C,Watts NB,De Santis M,et al.Acute phase reactions after zoledronic acid infusion:protective role of 25-hydroxyvitamin D and previous oral bisphosphonate therapy [J].Endocr Pract,2018,24(5):405-410.DOI:10.4158/EP161638.OR.
[20] Spängeus A,Johansson S,Woisetschläger M.Adherence to and persistence with zoledronic acid treatment for osteoporosis-reasons for early discontinuation [J].Arch Osteoporos,2020,15(1):58.DOI:10.1007/s11657-020-00733-4.
[21] Black DM,Reid IR,Napoli N,et al.The interaction of acute-phase reaction and efficacy for osteoporosis after zoledronic acid:HORIZON pivotal fracture trial [J].J Bone Miner Res,2022,37(1):21-28.DOI:10.1002/jbmr.4434.
[22] Okimoto N,Sakai A,Yoshioka T,et al.Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions:randomized,open-label,Japanese oz study [J].J Bone Miner Metab,2020,38(2):230-239.DOI:10.1007/s00774-019-01050-8.
[23] Merlotti D,Rendina D,Muscariello R,et al.Preventive role of vitamin D supplementation for acute phase reaction after bisphosphonate infusion in Paget's disease [J].J Clin Endocrinol Metab,2020,105(3):dgz138.DOI:10.1210/clinem/dgz138.
[24] Hewitt RE,Lissina A,Green AE,et al.The bisphosphonate acute phase response:rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins [J].Clin Exp Immunol,2005,139(1):101-111.DOI:10.1111/j.1365-2249.2005.02665.x.
[25] Schneiders FL,Huijts CM,Reijm M,et al.The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9vδ2-T cells in patients with advanced cancer [J].Immunobiology,2018,223(2):171-177.DOI:10.1016/j.imbio.2017.10.029.